More frequent serum potassium monitoring is advised in patients receiving concomitant therapy with drugs or supplements that increase serum potassium.
- TRADE NAME: Kerendia (Bayer)
- INDICATIONS: Reduction of the risk of hospitalization and mortality in patients with, for example, heart failure, chronic kidney disease.
- CLASS: Aldosterone antagonist / mineralocorticoid receptor antagonist (MRA)
- HALF-LIFE: 2–3 hours
- FDA APPROVAL DATE: 07/09/2021
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amiodarone, CYP3A4 inducers, CYP3A4 inhibitors, Efavirenz, Erythromycin, Grapefruit Juice, Itraconazole - PREGNANCY: No available data in pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.
Please login to view the rest of this drug profile.
Page last updated 09/29/2024
